PHIO

Strategic milestone advancements for lead clinical candidate PH-762 Initiation of commercial scale API, long term non-clinical toxicology, completion of Phase 1b pharmacology, and new IP announcements King of Prussia, Pennsylvania--(Newsfile Corp. - August 6, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio today reported its financial results for the quarter ended June 30, 2026, and provided a business update.

Live Presentation and Q&A: Tuesday, July 28, 2026 12 PM EDT King of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead clinical candidate PH-762 for the treatment of cutaneous carcinomas.

Live Presentation and Q&A: Thursday, July 28, 2026 12 PM EDT King of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead clinical candidate PH-762 for the treatment of cutaneous carcinomas.

Brings extensive experience in patient care, dermatologic research and commercialization King of Prussia, Pennsylvania--(Newsfile Corp. - July 21, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio is pleased to announce that R.

Securing additional patent protection in the United States, Canada, and Japan for INTASYL Compounds King of Prussia, Pennsylvania--(Newsfile Corp. - July 15, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today significant progress in the protection of its proprietary innovations across key international markets.

Live Presentation and Q&A: Tuesday, June 30, 2026 12 PM EDT King of Prussia, Pennsylvania--(Newsfile Corp. - June 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead clinical candidate PH-762 for the treatment of cutaneous carcinomas.

Nitto Denko Avecia begins first commercial-scale cGMP production of PH-762 drug substance Newly manufactured supply will support upcoming clinical trial in next development phase King of Prussia, Pennsylvania--(Newsfile Corp. - June 24, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company focused on developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer, today announced that the manufacture of the first commercial-scale cGMP batch of PH-762 drug substance has commenced at Nitto Denko Avecia, Inc. Phio entered into a comprehensive drug substance services agreement with Nitto Denko Avecia, Inc. in June 2025. Under the agreement to date, Avecia has successfully concluded a series of important preliminary activities that involve analytical and process development, method validation, cGMP manufacturing, and testing services for Phio's lead clinical development compound, PH-762.

Completion of Lead Clinical Candidate PH-762 Dose Escalation Trial for Treatment of Skin Cancer with Favorable Safety and Pathology Data Key Development Agreements Secured for Nonclinical Toxicology and U.S. cGMP Clinical Supply Manufacturing King of Prussia, Pennsylvania--(Newsfile Corp. - May 7, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio today reported its financial results for the quarter ended March 31, 2026, and provided a business update.

Phio invites investors, advisors and analysts with an interest in the life sciences sector to attend this virtual event R. Todd Plott, M.D.